NASDAQ · STOK
Stoke Therapeutics, Inc.
$26.20-$0.15 (-0.57%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
Loading market information…
NASDAQ · ADRX · USD
Stock price, earnings
Quote as of Oct 30, 2026, 02:15 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ADARx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ADARx Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $33.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
KEEP COMPARING
$26.20-$0.15 (-0.57%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
$19.76-$0.05 (-0.23%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$9.38-$0.33 (-3.35%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 38.89% below the high.
$4.80-$0.45 (-8.49%)
Prime Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.87% below the high.
$3.49-$0.14 (-3.86%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.92% below the high.
$11.07-$1.08 (-8.89%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.36% below the high.
$8.55-$0.28 (-3.17%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.74% below the high.
$1.36-$0.08 (-5.56%)
ProQR Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 51.6% below the high.
